Table 2 Association of the expression profile of TYROBP mRNA with clinicopathological factors of low-grade glioma
Characteristic | Low expression of TYROBP | High expression of TYROBP | p |
|---|---|---|---|
n | 264 | 264 | Â |
WHO grade, n (%) | Â | Â | 0.002 |
 G2 | 128 (27.4%) | 96 (20.6%) |  |
 G3 | 103 (22.1%) | 140 (30%) |  |
IDH status, n (%) | Â | Â | < 0.001 |
 WT | 29 (5.5%) | 68 (13%) |  |
 Mut | 233 (44.4%) | 195 (37.1%) |  |
1p/19q codeletion, n (%) | Â | Â | < 0.001 |
 codel | 139 (26.3%) | 32 (6.1%) |  |
 non-codel | 125 (23.7%) | 232 (43.9%) |  |
Age, meidan (IQR) | 41 (33, 52.25) | 39 (32, 53) | 0.674 |
P53 status, n (%) | Â | Â | < 0.001 |
 WT | 172 (42.79%) | 101 (25.12%) |  |
 Mut | 79 (19.65%) | 150 (37.31%) |  |
ATRX status, n (%) | Â | Â | < 0.001 |
 WT | 198 (39.44%) | 135 (26.89%) |  |
 Mut | 53 (10.56%) | 116 (23.11%) |  |